Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
CME Credit Available: Maximum of 6.0 AMA PRA Category 1 Credits™
Release Date: March 24, 2008
Expiration Date: March 24, 2009
This activity consists of audio and visual recording of 8 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Design antiretroviral strategies that consider current data on:
- The appropriate initiation of antiretroviral therapy
- The management of complicated failure and the role of resistance testing
- Drug-drug interactions among antiretrovirals and with other medications
- The status of investigational antiretroviral drugs
- Describe the state of the HIV pandemic and its implications on clinical care
- Identify the malignancies emerging in the current era of HIV management
- Formulate appropriate management strategies for HIV coinfection with multidrug-resistant and extensively drug-resistant tuberculosis
- List recent developments in HIV vaccine research efforts
CME Credit
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of
6.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Gerald H. Friedland, MD
Professor of Medicine, Epidemiology, and Public Health
Yale University School of Medicine
Director, AIDS Care Program
Yale-New Haven Hospital
New Haven, Connecticut
Paul A. Volberding, MD
Marvin Sleisenger Professor of Medicine
Vice-Chair, Department of Medicine
University of California San Francisco
Chief of Medical Service
San Francisco Veterans Affairs Medical Center
San Francisco, California
Speakers
Kevin M. De Cock, MD
Director
Department of HIV/AIDS
World Health Organization
Geneva, Switzerland
Charles W. Flexner, MD
Professor of Medicine, Pharmacology,
and International Health
Johns Hopkins University School of Medicine
Baltimore, Maryland
Scott M. Hammer, MD
Professor of Medicine
Columbia University College of Physicians
and Surgeons
Chief, Division of Infectious Diseases
Columbia University Medical Center
New York, New York
David M. Margolis, MD
Professor of Medicine, Microbiology and Immunology, and Epidemiology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Michael S. Saag, MD
Volunteer Member, Board of Directors
International AIDS Society-USA
Professor of Medicine
Director, Division of Infectious Diseases
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Kimberly Y. Smith, MD, MPH
Associate Professor of Medicine
Rush University Medical Center
Chicago, Illinois
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research grants awarded to University of California, San Diego from Gilead Sciences. Dr Benson served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Merck, and Pfizer, and chaired Data and Safety Monitoring Boards for Johnson & Johnson Research, Ltd. (Australia) and Achillion. (Updated 02/15/08)
Judith S. Currier, MD
Dr Currier (3/12/07-2/15/08) received research grants to UCLA from Tibotec, Merck, GlaxoSmithKline and Theratechnologies and served as a consultant or received honoraria from Bristol-Myers Squibb, Pfizer, Merck, and Tibotec. In addition she serves on a data safety monitoring board for Koronnis and Achillion Pharmaceuticals. (Updated 02/15/08)
Carlos del Rio, MD
Dr del Rio (3/12/07–2/15/08) received research grants to Emory University from Merck, GlaxoSmithKline, Pfizer, the CDC and the NIH. He served as a consultant or received honoraria from Merck, Trinity Biotech and BMS. (Updated 02/15/08)
Joel E. Gallant, MD, MPH
Dr Gallant received research grants awarded to Johns Hopkins University School of Medicine from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, RAPID Pharmaceuticals, Schering Plough, Tibotec, and Vertex. He is a member of Data Safety and Monitoring Boards for Abbott, Gilead, and Koronis. (Updated 02/15/08)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants to Cornell University from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as an ad-hoc scientific advisor or consultant to Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Schering, Trimeris, Virco, and Virostatics. He also serves as Chair of a DSMB for Koronis. (Updated 02/17/08)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 02/15/08)
Douglas D. Richman, MD
Dr Richman served as a consultant to Anadys, Biota, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Idinex, Koronis, Merck, Monogram, Pfizer, Roche, and Tobira. (Updated 02/19/08)
Michael S. Saag, MD
Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 03/05/08)
Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram, Pfizer, TaiMed, Tibotec, and Vertex. He had stock options for Archillion and Monogram. (Updated 01/15/08)
Paul A. Volberding, MD
Dr Volberding, during the period from 1/1/07 through 1/1/08, served on scientific advisory boards for Bristol-Myers Squibb, Gilead, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering for an ongoing clinical trial. He received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 03/05/08)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr De Cock had no relevant financial affiliations to disclose. (Updated 03/05/08)
Dr Flexner received research support or honoraria from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Tibotec, and Vertex. He served as a consultant to Boehringer Ingelheim, Inhibitex, Schering-Plough, and Sequoia Pharmaceuticals. (Updated 03/05/08)
Dr Friedland had no relevant financial affiliations to disclose. (Updated 03/05/08)
Dr Hammer received consulting fees from Merck and Wyeth. (Updated 03/05/08)
Dr Margolis received research support from Merck, Trimeris, and Roche, and has been a scientific advisor to Bristol-Myers Squibb, GlaxoSmithKline, Merck, Abbott and Pfizer. He has Gilead common stock. (Updated 03/05/08)
Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 03/05/08)
Dr Smith served on scientific advisory boards and or speakers’ bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer and Tibotec. (Updated 03/05/08) Dr Volberding, during the period from 1/1/07 through 1/1/08, served on scientific advisory boards for Bristol-Myers Squibb, Gilead, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering for an ongoing clinical trial. He received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 03/05/08)
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Ms Wilson has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Merck & Co., Inc.
Pfizer Global Pharmaceuticals
Generous Grants from:
GlaxoSmithKline
Additional grant support for this course:
Roche Laboratories
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2008@iasusa.org
